AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia drug in the ...

Preoperatively assessing anemia as a modifiable risk factor may counteract increased mortality risk for patients with severe ...

The FDA granted orphan designation to Sanofi US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Discover th ...

Changes associated with anemia tongue are called glossitis, otherwise known as tongue inflammation. This article explains why ...

Dr Ravinder K Gupta, Dr Akhilpreet Kaur Anemia is a serious global public health problem that particularly affects young ...

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Air pollution and vitamin B12 deficiency are emerging as major causes of India's rising anaemia crisis, beyond iron ...

Simmie White is taking control of her own story. The six-year-old girl and her mother want others to understand more about ...

AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.

Jindal Foundation's Kishori Express aids rural Odisha girls by tackling anemia through mobile healthcare and awareness ...